ASND

Ascendis Pharma

• TipRanks·05/20 09:16

  J.P. Morgan Remains a Buy on Ascendis Pharma (ASND)

• Seeking Alpha·05/19 18:01

  Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook

• Dow Jones·05/19 14:41

  Ascendis Pharma Initiated at Buy by Citigroup

• Dow Jones·05/19 14:41

  Ascendis Pharma Price Target Announced at $355.00/Share by Citigroup

• Benzinga·05/19 14:31

  Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355

• TipRanks·05/19 13:35

  StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls

• Simply Wall St·05/19 03:26

  Assessing Ascendis Pharma (ASND) Valuation After Recent Soft Trading And Perceived Discount

• TipRanks·05/18 20:26

  Ascendis Pharma initiated with a Buy at Citi

• TipRanks·05/18 12:59

  Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)

• Dow Jones·05/15 17:36

  Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

• Dow Jones·05/15 17:36

  Ascendis Pharma Price Target Raised to $329.00/Share From $324.00 by Evercore ISI Group

• Benzinga·05/15 17:26

  Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329

• TipRanks·05/15 12:41

  Ascendis Pharma price target raised to $329 from $324 at Evercore ISI

• Simply Wall St·05/15 11:30

  Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position

• TipRanks·05/13 20:29

  Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants